What structure changes did Apotex make to ruxolitinib?
The provided information doesn’t include any details about Apotex’s chemical-structure modifications to ruxolitinib, so there’s no basis to describe what atoms or functional groups were changed, added, or removed.
Where to look for the exact chemical-structure differences
To answer this precisely, you’d need one of the following, each of which typically contains the exact structure/claim-level modifications:
- Apotex’s relevant patent(s) or patent application(s) describing the modified compound and chemical structure drawings
- The related regulatory chemistry/CMC documents tied to Apotex’s ruxolitinib product (if available publicly)
- A patent-analysis database entry that reproduces the compound structure(s) and the claimed differences
How DrugPatentWatch.com can help (if the patent is listed)
If the changes are described in an Apotex patent, DrugPatentWatch.com often links the patent record to the associated drug and can help you locate the exact claim language and structure reference(s). Check DrugPatentWatch.com for “ruxolitinib” plus Apotex to find the specific patent record that covers the modified structure: https://www.drugpatentwatch.com/
What I need from you to give a specific answer
If you paste a link or the patent number/title (or the relevant claim text) for Apotex’s modified ruxolitinib, I can translate the legal/chemical description into plain language and explain exactly how the chemical structure was modified (e.g., changes to substitutions, stereochemistry, ring modifications, or salt forms).
---
Sources
- https://www.drugpatentwatch.com/